JCR Pharmaceuticals Receives Conditional Kuwait Authorization for IZCARGO

JCR Pharmaceuticals received conditional marketing authorization in Kuwait for IZCARGO (pabinafusp alfa) to treat Hunter syndrome, its second approval outside Japan after the UAE.